

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 August 2020 (13.08.2020)



(10) International Publication Number
WO 2020/161214 A1

(51) International Patent Classification:

A61K 47/68 (2017.01) *C07K 16/30* (2006.01)
A61P 35/00 (2006.01)

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(21) International Application Number:

PCT/EP2020/052932

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

06 February 2020 (06.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/802,511	07 February 2019 (07.02.2019)	US
19305173.7	11 February 2019 (11.02.2019)	EP
19305504.3	18 April 2019 (18.04.2019)	EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue La Boétie, 75008 PARIS (FR).

(72) Inventors: **ALLARD, Aurore**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR). **CHAD-JAA, Mustapha**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR). **COMBEAU, Cécile**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR). **DEMERS, Brigitte**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR). **HENRY, Christophe**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR). **YORUK, Semra**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR).

(74) Agent: **STEPHAN, Hélène**; c/o Sanofi, Patent Department, 54 rue La Boétie, 75008 PARIS (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF ANTI-CEACAM5 IMMUNOCONJUGATES FOR TREATING LUNG CANCER

(57) Abstract: The present disclosure provides methods of treating high CEACAM5 expressing cancers including lung cancers such as NSQ NSCLC using immunoconjugates comprising an antibody that specifically binds human CEACAM5.

WO 2020/161214 A1